medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

HIV co-infection is associated with lower tuberculosis bacterial burden independent of time to diagnosis in Botswana, a setting with widespread ART use

Juliana S. Chalfin[1]*, Chelsea R. Baker[1]*, Balladiah Kizito[2], Dimpho Otukile[2], Matsiri T. Ogopotse[2], Sanghyuk S. Shin[1], Chawangwa Modongo[2]****

[1]Sue & Bill Gross School of Nursing, University of California Irvine, Irvine, CA, USA

[2]Victus Global Botswana Organisation, Gaborone, Botswana

*Co-first author

**Co-senior author

Corresponding author:

Sanghyuk Shin, PhD

Associate Professor, Sue & Bill Gross School of Nursing

Director, UCI Infectious Disease Science Initiative

University of California Irvine

106F Berk Hall

Irvine, CA 92697

Email: ssshin2@uci.edu

Phone: 949-576-8675

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Abstract:

HIV co-infection has been shown to be associated with lower tuberculosis (TB) bacterial load in studies conducted prior to widespread availability of antiretroviral therapy (ART). We investigated associations between HIV co-infection and TB bacterial load, accounting for differences in time to TB diagnosis, in a high prevalence setting with widespread ART use. In Gaborone, Botswana, 268 sputum samples from people with newly diagnosed TB were tested with Xpert MTB/RIF Ultra (Xpert). TB bacterial load and time to TB diagnosis were estimated using mean Xpert cycle threshold (CT) and symptom duration, respectively. Multiple linear regression models and causal mediation analysis were used to determine the associations between HIV and Xpert CT and assess the mediating effect of symptom duration. Mean CT values were higher in people living with HIV compared to people without HIV (22.7 vs 20.3, $p < 0.001$). Among those living with HIV, there was a negative relationship between CD4 count and mean CT value (Spearman's rho -0.20, $p = 0.06$). After controlling for gender, age, and symptom duration, HIV status remained associated with CT value, with an average increase of 1.6 cycles ($p = 0.009$) among people with HIV and CD4 count > 200 cells/mm^3 and 2.1 cycles ($p = 0.002$) in those with a CD4 count ≤ 200 cells/mm^3 compared to individuals without HIV. Symptom duration was also found to be associated with CT value ($p < 0.05$). We found an indirect effect of HIV status on Xpert CT through the mediator, symptom duration ($\beta = 0.33$, $p = 0.048$), accounting for 13.5% of the relationship. Our findings suggest that time to TB diagnosis partially mediates the relationship between HIV status and CT value, but differences in pathophysiology between people with and without HIV likely play a dominant role in affecting TB bacterial burden.

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Introduction

Globally, tuberculosis (TB) has remained a leading cause of death due to an infectious disease with an estimated incidence of 10.0 million people with TB and 208,000 TB deaths among people living with HIV (1). While the World Health Organization (WHO) has provided goals to end the global TB epidemic, recent data indicate that targets for reduced incidence rates and deaths are not being met (2). In high burden areas, HIV poses as the greatest risk factor for developing TB, exacerbating existing susceptibility to primary infection or reactivation of latent TB (3). Southern Africa continues to report the highest prevalence of TB/HIV co-infection, demonstrating an urgent need to better understand TB transmission dynamics to reduce TB incidence and mortality (4).

The likelihood of TB transmission depends in part on the degree of infectiousness, which is often measured in clinical settings using bacterial load present in sputum (5). While this is commonly done using smear microscopy, Xpert MTB/RIF assays (Xpert) have been suggested as an alternative (6,7). Xpert is a diagnostic test that uses real-time polymerase chain reaction (PCR). Quantitative estimation of TB bacterial load can be inferred through cycle threshold (CT) values (8). CT values convey an inverse relationship to bacterial load as a higher CT value signifies lower bacterial load and lower CT value signifies higher bacterial load.

Sputum bacterial load is influenced by pathophysiology of active TB disease, which involves destruction of lung tissue, generating cavities that pass *M. tuberculosis* bacteria to airways (9). Therefore, the level of lung damage contributes to the transmission potential of a TB-infected individual. However, among people with HIV and TB, lower CD4+ T cell counts have been associated with reduced lung inflammation (9). The reduced inflammation can result in decreased cavitation, sputum bacterial load, and ultimately reduced infectiousness, as

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

suggested by the higher frequency of smear-negative pulmonary TB within untreated people living with HIV (9,10). For example, a previous study has corroborated the findings that increased immunosuppression, defined as CD4 count < 200 cells/mm^3, was associated with decreased bacterial burden, measured through CT values (6). Consequently, untreated HIV infection can change TB disease presentation and reduce TB infectiousness.

Bacterial burden may be impacted by delays in diagnosis, as the active disease state involves bacilli replication. Decreased TB bacterial burden with HIV co-infection may be partially related to early TB diagnosis and treatment initiation (9,10). Treatment for HIV typically involves frequent contact with the healthcare system, including increased opportunities for TB case finding and prompt treatment (9). Therefore, the association between HIV status and TB bacterial burden may be mediated by earlier TB diagnosis among people living with HIV.

Antiretroviral therapy (ART), the treatment of choice for managing HIV/AIDS, has significantly improved the quality of life of people living with HIV since it decreases the viral load and restores normal immune function against opportunistic pathogens (11). Access to effective treatment for HIV has greatly expanded, and as of 2020 an estimated 75% of people living with HIV (with known HIV status) were receiving ART (12). Further research is needed to understand its effect in settings with a high burden of both HIV and tuberculosis (9). As ART alters the disease process of HIV, there is a gap in knowledge of whether HIV-coinfection remains associated with reduced TB infectiousness during the present time when ART is widely available.

The purpose of this study was to determine associations between HIV co-infection and sputum TB bacterial load and assess whether differences in duration of symptoms mediates this association, in a high prevalence setting. This study could contribute to understanding how HIV-

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

coinfection affects infectiousness and transmission risk of TB in the current era of widespread ART use.

Methods

Study Design, Setting, and Population

Botswana is a country in southern Africa with a high burden of TB and among the highest rates of TB-HIV co-infection in the world. This cross-sectional analysis is part of an ongoing population-based TB transmission study in Gaborone, the capital city of Botswana. Participants were sequentially enrolled after diagnosis of TB from community or health care facilities. All participants were recruited in accordance with Botswana national guidelines. Active case finding, involving the screening of all patients, and passive case finding, involving clinical diagnosis of patients presenting with TB symptoms, were utilized in 26 public health facilities. Participants included male and female patients of all ages. Clinical and demographic data were collected through a standardized questionnaire that captured information about TB symptoms and their duration (< 1 month, 1-2 months, 2-3 months, and > 3 months prior to diagnosis). Smoking and alcohol use were collected as these variables are known to impact TB transmission as well as the immune system. Smoking has been shown to increase infectiousness by increasing the aerosolization of bacilli through changes in mucus and increased cough frequency (13). Furthermore, alcohol impairs the immune system leading to increased susceptibility to TB as well as reactivation and is associated with social environments that facilitate TB transmission (14). Participants provided their consent for us to access their medical records to collect TB and HIV history, including CD4 cell counts, viral load, and ART history. We recorded CT values for five probes in the Xpert (Xpert MTB/RIF Ultra) test used for clinical

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

diagnosis. Mean CT values across all probes was used as the primary measure of bacterial load. Participant-reported duration of symptoms was used as an approximate measure of time to diagnosis.

Statistical Analysis

Standard descriptive statistics were used to characterize the data. The sample population of CT values was compared between groups of participants by HIV status and CD4 count using the nonparametric Wilcoxon test. CT values were also compared between groups of participants by symptom duration using the Wilcoxon test to determine significant difference. Odds ratios were estimated using a dichotomous variable for symptom duration (< 1 month and ≥ 1 month) by HIV status and CD4 count category. Spearman correlation was used to assess the relationship between CD4 counts and mean CT values among participants living with HIV since values were not normally distributed. Bivariate linear regression was used to examine the association between mean CT value as the outcome variable and selected patient characteristics as predictor variables. Multivariate linear regression models were used to control for confounding variables including age and gender to examine the relationship with HIV status as the primary exposure variable of interest. We also compared multivariate models with and without symptom duration to estimate the extent to which the association between HIV status and bacterial load is explained by differences in time to diagnosis. Causal mediation analysis was performed using the R package mediation to determine the mediation effects of symptom duration, as a dichotomous variable, on the relationship between HIV status and CT value (15). Bootstrapping was used to test the significance of the indirect effect, using 500 samples. All statistical analyses were conducted using the R statistical software version 4.1.2 (16).

Ethics Approval

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

This study was approved by institutional review boards at the University of Irvine, California and Botswana Ministry of Health and Wellness Human Research Development Committee. All participants provided written consent for research use of clinical data.

Results

Sample Population

During January 2021 to August 2022, 379 participants had positive Xpert results, of which 338 participants had valid corresponding Xpert CT value results. Of those, 70 individuals (20.7%) were excluded from analysis due to missing HIV results (n=12), CD4 counts that were either missing (n=42) or taken greater than six months from the initial interview (n=13), or missing symptom duration (n=3). A total of 268 participants were included in our analysis. Overall, 68.7% were male, and the median age was 34 (interquartile range [IQR]: 25-45.25) (Table 1). People with HIV comprised 33.2% with a CD4 count median of 263 cells/mm^3 (IQR: 100-523). At the time of enrollment, 25% and 43.3% reported smoking and alcohol use, respectively. The proportion of participants reporting TB symptoms for < 1 month was 55.1% and 38.5% among people with and without HIV, respectively. Among individuals with HIV, 43.8% had CD4 counts of ≤ 200 cells/mm^3, 61.8% reported taking ART at the time of TB diagnosis, and median viral load was 30.0 copies/mL (IQR: ≤20-400; Figure 1).

Table 1: Demographic and Clinical Information by HIV Status of Individuals in Botswana 2021-2022

	Negative (N=179)	Positive (N=89)	Overall (N=268)
Gender			
Female	57 (31.8%)	27 (30.3%)	84 (31.3%)
Male	122 (68.2%)	62 (69.7%)	184 (68.7%)
Age			
0-19	18 (10.1%)	0 (0%)	18 (6.7%)
20-29	72 (40.2%)	10 (11.2%)	82 (30.6%)

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

30-39	42 (23.5%)	29 (32.6%)	71 (26.5%)
40-49	19 (10.6%)	28 (31.5%)	47 (17.5%)
50-65	17 (9.5%)	22 (24.7%)	39 (14.6%)
65+	11 (6.1%)	0 (0%)	11 (4.1%)
Currently Smoking			
Yes	44 (24.6%)	23 (25.8%)	67 (25.0%)
No	135 (75.4%)	66 (74.2%)	201 (75.0%)
Currently Drinking Alcohol			
Yes	78 (43.6%)	38 (42.7%)	116 (43.3%)
No	101 (56.4%)	51 (57.3%)	152 (56.7%)
Symptom Duration			
<1 month	69 (38.5%)	49 (55.1%)	118 (44.0%)
1-2 months	70 (39.1%)	27 (30.3%)	97 (36.2%)
2-3 months	16 (8.9%)	9 (10.1%)	25 (9.3%)
3+ months	24 (13.4%)	4 (4.5%)	28 (10.4%)
HIV Status			
HIV-	179 (100%)	0 (0%)	179 (66.8%)
HIV+ CD4 > 200	0 (0%)	50 (56.2%)	50 (18.7%)
HIV+ CD4 ≤ 200	0 (0%)	39 (43.8%)	39 (14.6%)

Figure 1: (A) Histogram of individuals' mean CT values among all participants. (B) Histogram of individuals' CD4 counts among participants living with HIV. (C) Histogram of individuals' viral load among participants living with HIV. (D) Bar graph of frequency, measured in percent, of ART history among participants living with HIV.

Symptom Duration

The percentage of participants experiencing symptoms >1 month was 61.5% among people without HIV, 48% among those with HIV and CD4 counts > 200 cells/mm^3, and 41% among those with HIV and CD4 counts ≤ 200 cells/mm^3 (Figure 2). Participants living with HIV with CD4 counts ≤ 200 cells/mm^3 had significantly decreased odds of symptom duration >1 month compared to those without HIV (OR 0.44, p = 0.021), but no statistically significant difference was found between people with HIV and CD4 count >200 cells/m3 and people without HIV (Table 2).

Figure 2: Comparison of symptom duration length between HIV status.

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

Table 2. Odds ratio for Symptom Duration Greater than 1 Month by HIV Status and CD4 Count Breakdown

Characteristic	OR[1]	95% CI[1]	p-value
HIV status			
HIV-	—	—	
HIV+ CD4 > 200	0.58	0.31, 1.09	0.090
HIV+ CD4 ≤ 200	0.44	0.21, 0.88	0.021

[1]OR = Odds Ratio, CI = Confidence Interval

Distribution of CT Value

The mean CT value across all participants was 21.1 (IQR: 18.1-23.1) with a range of 17.1-33.9 (Figure 1A). Mean CT values were higher among people living with HIV in comparison to people without HIV (22.7 vs 20.3, $p < 0.001$) (Figure 3A). This was noted for those with CD4 >200 cells/mm^3 ($p = 0.009$) as well as ≤ 200 cells/mm^3 ($p < 0.001$). However, the difference between participants in the two CD4 count categories was not significant (23.0 vs 23.3 for CD4 >200 cells/mm^3 and ≤ 200 cells/mm^3, respectively, $p = 0.34$).

Figure 3: (A) Boxplot comparing mean CT values between HIV status and CD4 count, among those living with HIV. (B) Boxplot comparing mean CT values between groups of symptoms duration prior to diagnosis, measured in months. (C) Scatterplot comparing mean CT values and CD4 cell counts among participants with HIV.

Among participants living with HIV, there was a weak negative correlation between CD4 count and mean CT value (Spearman's rho -0.2; $p = 0.06$; Figure 3C). Participants who reported symptoms for < 1 month had higher mean CT values compared to those that reported symptoms for 1-2 months, 2-3 months, and > 3 months prior to diagnosis ($p = 0.013$; $p = 0.013$; $p = 0.017$ respectively) (Figure 3B).

Individual Level Predictors of CT Value

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

In a bivariate linear regression model, compared to participants without HIV, mean CT values were increased by 2.1 ($p < 0.001$) in participants living with HIV with CD4 counts >200 cells/mm^3 and by an average of 2.7 ($p < 0.001$) in participants living with HIV with CD4 counts ≤ 200 cells/mm^3 (Table 3). The bivariate linear regression model displays a decreasing trend in mean CT values as the duration of symptoms increases.

Table 3. Bivariate Linear Regression Model for Mean CT Value among All Participants

Characteristic	N	Beta	95% CI[1]	p-value
Gender	268			
Female		—	—	
Male		-0.43	-1.4, 0.59	0.41
Age	268	0.06	0.03, 0.09	<0.001
Currently Smoking	268			
Yes		—	—	
No		0.86	-0.23, 2.0	0.12
Currently Drinking Alcohol	268			
Yes		—	—	
No		0.36	-0.59, 1.3	0.46
Symptom Duration	268			
<1 month		—	—	
1-2 months		-1.5	-2.5, -0.42	0.006
2-3 months		-2.6	-4.2, -0.92	0.002
3+ months		-2.4	-4.0, -0.81	0.003
HIV Status	268			
HIV-		—	—	
HIV+ CD4 > 200		2.1	0.89, 3.3	<0.001
HIV+ CD4 ≤ 200		2.7	1.3, 4.0	<0.001
CD4 Count	89	0.00	-0.01, 0.00	0.11
Viral Load	77	0.00	0.00, 0.00	0.57
ART History	85			
Patient has never taken ARTs		—	—	
Patient is taking ARTs		-0.42	-2.5, 1.7	0.70
Patient took ARTs but stopped		-3.7	-7.4, -0.02	0.049

[1]CI = Confidence Interval

multivariate linear regression model, HIV status, including the CD4 count breakdown for participants with HIV, and symptom duration were significant predictors of mean CT (Table 4). When controlling for gender, age, and symptom duration, the mean CT value was 1.6 cycles

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

higher (p = 0.009) among people with HIV and CD4 count > 200 cells/mm^3 and 2.1 cycles higher (p = 0.002) in those with a CD4 count ≤ 200 cells/mm^3 compared with the reference group of individuals without HIV. After controlling for gender, age, and HIV status, the mean CT value decreased by 1.1 cycles (p = 0.026), 2.2 cycles (p = 0.007), and 1.6 cycles (p = 0.043) for participants that reported TB symptoms 1-2 months, 2-3 months, and > 3 months, respectively, prior to diagnosis compared to those that reported symptoms < 1 month prior. The mean CT value also increased by 0.04 cycles with age as a continuous variable (p = 0.022) in the multivariate linear regression model controlling for gender, HIV status, and symptom duration. In a multivariate linear regression model that only included people with HIV, the association between CD4 count and CT did not reach statistical significance when controlling for gender, age, CD4 count, viral load, and ART History (p= 0.2; Table 5).

Table 4. Multivariate Regression Models for Mean CT among All Participants

	Excluding Symptom Duration			Including Symptom Duration		
Characteristic	Beta	95% CI[1]	p-value	Beta	95% CI[1]	p-value
Gender						
Female	—	—		—	—	
Male	-0.70	-1.7, 0.28	0.2	-0.69	-1.7, 0.29	0.2
Age	0.04	0.01, 0.08	0.007	0.04	0.01, 0.07	0.022
HIV Status						
HIV-	—	—		—	—	
HIV+ CD4 > 200	1.7	0.53, 2.9	0.005	1.6	0.40, 2.8	0.009
HIV+ CD4 ≤ 200	2.3	1.0, 3.6	<0.001	2.1	0.78, 3.4	0.002
Symptom Duration						
<1 month				—	—	
1-2 months				-1.1	-2.2, -0.14	0.026
2-3 months				-2.2	-3.8, -0.62	0.007

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

3+ months		-1.6	-3.2, -0.05	0.043

[1]CI = Confidence Interval

Table 5. Multivariate Regression Model for Mean CT among Participants Living with HIV

Characteristic	Beta	95% CI[1]	p-value
Gender			
Female	—	—	
Male	-0.44	-2.8, 1.9	0.7
Age	0.02	-0.09, 0.13	0.7
CD4 Count by 10	-0.03	-0.07, 0.02	0.2
Log10 Viral Load	0.31	-0.76, 1.4	0.6
ART History			
Patient has never taken ARTs	—	—	
Patient is taking ARTs	-0.03	-2.8, 2.7	>0.9
Patient took ARTs but stopped	-3.7	-8.0, 0.54	0.086

[1]CI = Confidence Interval

The mediation analysis found a total effect of HIV status of CT value of $\beta = 2.3$ ($p < 0.001$; Table 6). The indirect effect through the mediator, symptom duration, was statistically significant ($\beta = 0.33$, $p = 0.048$) with mediation accounting for 13.5% of the relationship. The direct effect of HIV status on Xpert CT remained statistically significant ($\beta = 2.1$, $p < 0.001$).

Table 6: Mediation Analysis of the association between HIV status and mean Xpert CT values with symptom duration as mediator among people newly diagnosed with tuberculosis in Botswana

	Estimate	p-value
Indirect Effect	0.326	0.048
Direct Effect	2.085	<0.001
Total Effect	2.411	<0.001
Prop. Mediated	0.135	0.048

Discussion

Using mean CT as a measure of TB bacterial burden, we found an association between decreased sputum bacterial burden and increased immunosuppression among people living with HIV in a high burden setting during the time of widespread access to ART. Additionally,

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

increase in duration of symptoms was associated with decrease in mean CT values, indicating an increase in sputum bacterial burden. Our findings are consistent with earlier findings that those living with HIV experience lower TB sputum bacterial burden compared to those without HIV (6, 8). For example, Burger et al. compared CT values from sputum and saliva from both people living with and without HIV, and concluded that patients living with HIV had significantly lower bacterial load than individuals without HIV (17). However, prior studies did not investigate the mediating role of time to TB diagnosis. Our study findings support the observation that HIV changes the presentation of TB with a lower sputum TB bacterial load, potentially due to less inflammation and cavitation (6, 8).

As ART decreases the viral load and restores normal immune function, it has the potential to shift the TB disease presentation to be similar to those without HIV. A study using smear microscopy found that ART increased smear positivity and cavitation among participants with HIV, with lower proportions compared to individuals without HIV (18). As ART has a positive relationship with CD4 count, we expected higher CD4 counts among people with HIV in our study and similar levels of TB bacterial load by HIV status. However, our data show a significant proportion of people with HIV/TB co-infection have advanced immune suppression and, therefore, TB bacterial load remains lower among people living with HIV compared to those without HIV even in settings with widespread ART use.

Symptom duration prior to diagnosis can be used as a measure of diagnostic delay. Our data suggests a negative correlation between symptom duration and CT values after controlling for confounding variables. Previous studies suggest that people living with HIV are more likely to be diagnosed for TB faster due to more severe symptoms or increased contact with healthcare systems (9). Our data supports this finding since a significant difference was found between

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

participants with and without HIV with symptom duration for < 1 month before diagnosis. Our findings suggest that the association between HIV-associated immunosuppression and CT values is partially mediated by differences in timeliness of TB diagnosis between people with and without HIV. However, 86.5% of this association was not mediated by TB symptom duration, which suggests that differences in pathophysiology between people with and without HIV play a dominant role in affecting TB bacterial burden.

Limitations to our study include the cross-sectional design, which limits our ability to establish causal relationships. Predictors of CT values are important to understand since the level of bacterial load has implications for transmission. Future studies should examine HIV status in relation to TB transmission among close contacts to directly demonstrate the applicability of CT values in determining transmission risks.

In conclusion, our data demonstrate that HIV status remains a predictor of TB infectiousness even when ART is widely available. Duration of symptoms was found to partially mediate this relationship. Individuals living without HIV may be at a greater risk of transmitting TB to their contacts. Further research should directly assess TB outcomes and transmission based on CT results to advance understanding of its utility in clinical and community health practice.

Acknowledgements

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

We are grateful to the study participants who donated their time and clinical specimens to make this study possible.

References

1. World Health Organization. Global Tuberculosis Report 2021. [cited 2023 Jan 10]. Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports/global-tuberculosis-report-2021
2. World Health Organization. Tuberculosis (TB) [Internet]. [cited 2022 Jan 10]. Available from: https://www.who.int/news-room/fact-sheets/detail/tuberculosis
3. Bruchfeld J, Correia-Neves M, Källenius G. Tuberculosis and HIV Coinfection. Cold Spring Harb Perspect Med. 2015 Jul 1;5(7):a017871.
4. Akwafuo SE, Abah T, Oppong JR. Evaluation of the Burden and Intervention Strategies of TB-HIV Co-Infection in West Africa. J Infect Dis Epidemiol. 2020 Jul 10. 6:143. doi.org/10.23937/2474-3658/1510143
5. Dye C, Williams BG. The Population Dynamics and Control of Tuberculosis. Science. 2010 May 14;328(5980):856–61.
6. Hanrahan CF, Theron G, Bassett J, Dheda K, Scott L, Stevens W, et al. Xpert MTB/RIF as a Measure of Sputum Bacillary Burden. Variation by HIV Status and Immunosuppression. Am J Respir Crit Care Med. 2014 Jun;189(11):1426–34.
7. Beynon F, Theron G, Respeito D, Mambuque E, Saavedra B, Bulo H, et al. Correlation of Xpert MTB/RIF with measures to assess Mycobacterium tuberculosis bacillary burden in high HIV burden areas of Southern Africa. Sci Rep. 2018 Mar 26;8(1):5201.

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

8. Lawn SD, Nicol MP. Xpert® MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol. 2011 Sep;6(9):1067–82.
9. Peters JS, Andrews JR, Hatherill M, Hermans S, Martinez L, Schurr E, et al. Advances in the understanding of Mycobacterium tuberculosis transmission in HIV-endemic settings. Lancet Infect Dis. 2019 Mar 1;19(3):e65–76.
10. Kwan CK, Ernst JD. HIV and Tuberculosis: a Deadly Human Syndemic. Clin Microbiol Rev. 2011 Apr;24(2):351–76.
11. Treatment [Internet]. 2021 [cited 2023 Jan 10]. Available from: https://www.cdc.gov/hiv/basics/livingwithhiv/treatment.html
12. UNAIDS data 2020 [Internet]. [cited 2022 Mar 27]. Available from: https://www.unaids.org/en/resources/documents/2020/unaids-data
13. Turner RD, Bothamley GH. Smoking and the Transmission of Tuberculosis. Pediatr Infect Dis J. 2015 Oct;34(10):1138.
14. Imtiaz S, Shield KD, Roerecke M, Samokhvalov AV, Lönnroth K, Rehm J. Alcohol consumption as a risk factor for tuberculosis: meta-analyses and burden of disease. Eur Respir J. 2017 Jul;50(1):1700216.
15. Tingley D, Yamamoto T, Hirose K, Keele L, Imai K. mediation□: *R* Package for Causal Mediation Analysis. J Stat Softw [Internet]. 2014 [cited 2022 Dec 13];59(5). Available from: http://www.jstatsoft.org/v59/i05/
16. R Core Team. R: A language and environment for statistical computing; 2018.

medRxiv preprint doi: https://doi.org/10.1101/2022.03.28.22273071; this version posted January 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

17. Burger ZC, Aung ST, Aung HT, Rodwell T, Seifert M. 658. Effect of HIV Status on Tuberculosis Load as Detected by Xpert MTB/RIF in Sputum vs. Saliva Samples. Open Forum Infect Dis. 2020 Oct 1;7(Supplement_1):S385–6.

18. Munthali L, Khan PY, Mwaungulu NJ, Chilongo F, Floyd S, Kayange M, et al. The effect of HIV and antiretroviral therapy on characteristics of pulmonary tuberculosis in northern Malawi: a cross-sectional study. BMC Infect Dis. 2014 Feb 25;14(1):107.


Distribution of CT Values
Count
75
50
25
0
20
25
30
CT Values
Distribution of CD4 Counts
Count
20
15
10
5
0
0
500
1000
CD4 Count
Distribution of Viral Load
Count
25
20
15
10
5
0
2
4
6
log(viral load)
ART History Frequency
Count
40
20
0
Currently Taking
Never
Stopped
NA
ART History


Percent with symptoms > 1 month by HIV status
Percent
60
40
20
0
HIV-
HIV+ CD4 > 200
HIV+ CD4 ≤ 200
HIV status


Boxplot of CT Values by HIV Category
<0.001
0.009
0.34
CT Value
35
30
25
20
HIV-
HIV+ CD4 > 200
HIV+ CD4 ≤ 200
HIV Status and CD4 Count


Boxplot of CT Values by Symptom Duration
CT Value
30
25
20
<1 month
1-2 months
2-3 months
3+ months
Symptom Duration


Scatterplot of CT Values vs CD4 Cell Counts
R = – 0.2, p = 0.061
CT Value
32
28
24
20
0
250
500
750
1000
1250
CD4 Cell Count